Metabolomic and molecular insights into sickle cell disease and innovative therapies
- 23 April 2019
- journal article
- review article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (8) , 1347-1355
Abstract
Sickle cell disease (SCD) is an autosomal-recessive hemolytic disorder with high morbidity and mortality. The pathophysiology of SCD is characterized by the polymerization of deoxygenated intracellular sickle hemoglobin, which causes the sickling of erythrocytes. The recent development of metabolomics, the newest member of the “omics” family, has provided a powerful new research strategy to accurately measure functional phenotypes that are the net result of genomic, transcriptomic, and proteomic changes. Metabolomics changes respond faster to external stimuli than any other “ome” and are especially appropriate for surveilling the metabolic profile of erythrocytes. In this review, we summarize recent pioneering research that exploited cutting-edge metabolomics and state-of-the-art isotopically labeled nutrient flux analysis to monitor and trace intracellular metabolism in SCD mice and humans. Genetic, structural, biochemical, and molecular studies in mice and humans demonstrate unrecognized intracellular signaling pathways, including purinergic and sphingolipid signaling networks that promote hypoxic metabolic reprogramming by channeling glucose metabolism to glycolysis via the pentose phosphate pathway. In turn, this hypoxic metabolic reprogramming induces 2,3-bisphosphoglycerate production, deoxygenation of sickle hemoglobin, polymerization, and sickling. Additionally, we review the detrimental role of an impaired Lands’ cycle, which contributes to sickling, inflammation, and disease progression. Thus, metabolomic profiling allows us to identify the pathological role of adenosine signaling and S1P-mediated erythrocyte hypoxic metabolic reprogramming and hypoxia-induced impaired Lands' cycle in SCD. These findings further reveal that the inhibition of adenosine and S1P signaling cascade and the restoration of an imbalanced Lands' cycle have potent preclinical efficacy in counteracting sickling, inflammation, and disease progression.Keywords
This publication has 60 references indexed in Scilit:
- Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and InterventionsPLOS Medicine, 2013
- Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediatorsBlood, 2012
- Metabolomics: the apogee of the omics trilogyNature Reviews Molecular Cell Biology, 2012
- Priapism in Sickle-Cell Disease: A Hematologist’s PerspectiveThe Journal of Sexual Medicine, 2012
- Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell diseaseBlood, 2011
- Sphingosine-1-phosphate acting via the S1P1 receptor is a downstream signaling pathway in ceramide-induced hyperalgesiaNeuroscience Letters, 2011
- A2B Adenosine Receptor–Mediated Induction of IL-6 Promotes CKDJournal of the American Society of Nephrology, 2011
- Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A 2B adenosine receptor signalingThe FASEB Journal, 2009
- The vascular S1P gradient—Cellular sources and biological significanceBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2008
- Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26Blood, 2006